Method for diagnosing multiple sclerosis
Disclosed is a method for diagnosing multiple sclerosis and more particularly to a method for diagnosing multiple sclerosis by measuring levels of antibodies to glycans in a biological sample.
1. A method of predicting whether a subject with a First Neurological Event (FNE) will develop relapsing remitting multiple sclerosis (RRMS) or whether a subject with a FNE will develop other neurological disease (OND), the method comprising:
providing a blood sample from a subject at FNE;
detecting in said blood sample an anti-Glc(α1,4)Glc(α) (GAGA4) IgM isotype antibody and an anti-Glc(α1,6)Glc(α) (GAGA6) IgM isotype antibody;
comparing the levels of said antibodies in said blood sample to levels of said antibodies in individuals with OND; and
differentiating an FNE subject predicted to develop RRMS from an FNE subject predicted to develop OND by detection of a higher level of said antibodies in said blood sample compared to an OND level of said antibodies.
2. The method of claim 1 , wherein said subject with a First Neurological event (FNE) has symptoms of a Clinically Isolated Syndrome (CIS) suggestive of multiple sclerosis.
3. The method of claim 1 , wherein said subject is a female.
4. The method of claim 1 , wherein said subject is a male.
5. The method of claim 1 , wherein said antibody is detected using a glycan containing a Glc(α1,4)Glc(α) (GAGA4) or a Glc(α1,6)Glc(α) (GAGA6) linkage.
6. The method of claim 1 , wherein said antibody is detected using an oligosaccharide that includes a glycan containing a Glc(α1,4)Glc(α) (GAGA4) or a Glc(α1,6)Glc(α) (GAGA6) linkage.
7. The method of claim 1 , wherein said antibody is detected using a polymer that includes a glycan containing a Glc(α1,4)Glc(α) (GAGA4) or a Glc(α1,6)Glc(α) (GAGA6) linkage.
8. The method of claim 1 , wherein said polymer is a polysaccharide.
9. The method of claim 7 , wherein said polymer is naturally occurring.
10. The method of claim 7 , wherein said polymer is a synthetic polymer.